The startup has developed a patented in vitro diagnostics device that utilizes magnetic particles in a portable, battery-operated reader with a single-use cartridge for various applications. This technology enables non-invasive detection of celiac disease, enhancing rapid diagnostics for human and veterinary health, as well as food and environmental safety.
Funding
$970K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic methods for conditions like celiac disease, neonatal sepsis, and viral outbreaks in poultry often rely on time-consuming lab procedures and specialized equipment. This can lead to delays in diagnosis and treatment, especially in low-resource settings or situations requiring rapid response.
Solution
BioEclosion is developing a range of rapid and portable in vitro diagnostic devices based on a patented technology that utilizes magnetic particles and electrochemical genosensing. Their platform consists of a portable, battery-operated reader and single-use cartridges tailored for various applications, including human health (celiac disease, neonatal sepsis) and veterinary health (avian viral outbreaks). The technology enables rapid, on-site detection of target analytes, reducing turnaround times and minimizing the need for specialized laboratory infrastructure. The core technology involves using tailored DNA/RNA probes with magnetic actuation to enhance sensitivity and specificity.
Target Audience
The primary target audience includes healthcare providers needing rapid diagnostic tools for celiac disease and neonatal sepsis, as well as veterinary professionals and poultry farmers requiring on-site testing for viral outbreaks.
Features
- Portable, battery-operated reader for on-site diagnostics
- Single-use cartridges for various applications (Celiac disease, neonatal sepsis (GBS), Avian Influenza Virus (AIV), Newcastle Disease Virus (NDV) and Infectious Bronchitis Virus (IBV))
- Rapid results, with some tests providing results in as little as 15-30 minutes
- Utilizes magnetic particles and electrochemical genosensing for enhanced sensitivity
- Integrates tailored designed DNA/RNA probes for specific target detection
- Potential for non-invasive detection methods
- Customizable platform adaptable for detecting novel strains and other infectious diseases